{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:54:18Z","timestamp":1789152858813,"version":"build-2803163510"},"reference-count":30,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2019,4,26]]},"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The Its Not JUST Idiopathic pulmonary fibrosis Study (INJUSTIS) is a multicentre, prospective, observational cohort study. The aims of this study are to identify genetic, serum and other biomarkers that may identify specific molecular mechanisms, reflecting disease endotypes that are shared among patients with progressive pulmonary fibrosis regardless of aetiology. Furthermore, it is anticipated that these biomarkers will help predict fibrotic activity that may identify patterns of disease behaviour with greater accuracy than current clinical phenotyping.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>200 participants with the multidisciplinary team confirmed fibrotic lung disease (50 each of rheumatoid-interstitial lung disease (ILD), asbestosis, chronic hypersensitivity pneumonitis and unclassifiable ILD) and 50 idiopathic pulmonary fibrosis participants, recruited as positive controls, will be followed up for 2 years. Participants will have blood samples, lung function tests, quality of life questionnaires and a subgroup will be offered bronchoscopy. Participants will also be given the option of undertaking blinded home handheld spirometry for the first 3 months of the study. The primary end point will be identification of a biomarker that predicts disease progression, defined as 10% relative change in forced vital capacity (FVC) or death at 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The trial has received ethical approval from the National Research Ethics Committee Nottingham (18\/EM\/0139). All participants must provide written informed consent. The trial will be overseen by the INJUSTIS steering group that will include a patient representative, and an independent chairperson. The results from this study will be submitted for publication in peer-reviewed journals and disseminated at regional and national conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03670576\">NCT03670576<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2019-000439","type":"journal-article","created":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T06:45:34Z","timestamp":1559717134000},"page":"e000439","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["The Its Not JUST Idiopathic pulmonary fibrosis Study (INJUSTIS): description of the protocol for a multicentre prospective observational cohort study identifying biomarkers of progressive fibrotic lung disease"],"prefix":"10.1136","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct03670576","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0796-5724","authenticated-orcid":false,"given":"Fasihul","family":"Khan","sequence":"first","affiliation":[{"name":"Respiratory Medicine, University of Nottingham, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1340-2688","authenticated-orcid":false,"given":"Iain","family":"Stewart","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Public Health, University of Nottingham, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Howard","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, University of Nottingham, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia M","family":"McKeever","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Public Health, University of Nottingham, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Jones","sequence":"additional","affiliation":[{"name":"Action for Pulmonary Fibrosis, City Wharf, Davidson Road, Lichfield, Staffordshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Hearson","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, University Of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Braybrooke","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, University of Nottingham, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Edwards","sequence":"additional","affiliation":[{"name":"patientMpower Ltd, The Digital Depot, Thomas Street, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisli","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, University of Nottingham, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri","family":"Saini","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, University of Nottingham, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,6,4]]},"reference":[{"key":"2025083110540000000_6.1.e000439.1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.148031"},{"key":"2025083110540000000_6.1.e000439.2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1164\/rccm.201208-1544CI","article-title":"Fibrosing interstitial lung disease. A practical high-resolution computed Tomography\u2013based approach to diagnosis and management and a review of the literature","volume":"188","author":"Hodnett","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083110540000000_6.1.e000439.3","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (capacity): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"The Lancet"},{"key":"2025083110540000000_6.1.e000439.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2025083110540000000_6.1.e000439.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2025083110540000000_6.1.e000439.6","unstructured":"NICE . Idiopathic pulmonary fibrosis in adults: diagnosis and management, 2013."},{"key":"2025083110540000000_6.1.e000439.7","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S2213-2600(15)00048-X","article-title":"Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre profile study","volume":"3","author":"Jenkins","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2025083110540000000_6.1.e000439.8","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S2213-2600(17)30430-7","article-title":"An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre profile cohort study","volume":"5","author":"Maher","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2025083110540000000_6.1.e000439.9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1164\/rccm.201511-2152OC","article-title":"Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis","volume":"194","author":"Russell","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083110540000000_6.1.e000439.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211138"},{"key":"2025083110540000000_6.1.e000439.11","doi-asserted-by":"crossref","unstructured":"Morisset J , Johannson KA , Jones KD , et al . Identification of diagnostic criteria for chronic hypersensitivity pneumonitis: an international modified Delphi survey. Am J Respir Crit Care Med 2018;197.doi:10.1164\/rccm.201710-1986OC","DOI":"10.1164\/rccm.201712-2403ED"},{"key":"2025083110540000000_6.1.e000439.12","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201611-2201PP","article-title":"Hypersensitivity pneumonitis: perspectives in diagnosis and management","volume":"196","author":"Vasakova","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083110540000000_6.1.e000439.13","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00131912"},{"key":"2025083110540000000_6.1.e000439.14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.resinv.2017.09.001","article-title":"Clinico-radio-pathological characteristics of unclassifiable idiopathic interstitial pneumonias","volume":"56","author":"Nakamura","year":"2018","journal-title":"Respir Investig"},{"key":"2025083110540000000_6.1.e000439.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013660"},{"key":"2025083110540000000_6.1.e000439.16","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S2213-2600(17)30216-3","article-title":"The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study","volume":"5","author":"Ley","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2025083110540000000_6.1.e000439.17","doi-asserted-by":"crossref","unstructured":"Juge P-A , Borie R , Kannengiesser C , et al . Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. Eur Respir J 2017;49.doi:10.1183\/13993003.02314-2016","DOI":"10.1183\/13993003.02314-2016"},{"key":"2025083110540000000_6.1.e000439.18","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"2025083110540000000_6.1.e000439.19","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"2025083110540000000_6.1.e000439.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5213.1665"},{"key":"2025083110540000000_6.1.e000439.21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/thorax.58.4.339","article-title":"Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ)","volume":"58","author":"Birring","year":"2003","journal-title":"Thorax"},{"key":"2025083110540000000_6.1.e000439.22","doi-asserted-by":"crossref","unstructured":"Stewart I , McKeever T , Braybrooke R , et al . Patient reported distress can aid clinical decision making in idiopathic pulmonary fibrosis: analysis of the profile cohort. bioRxiv 2018.","DOI":"10.1101\/460626"},{"key":"2025083110540000000_6.1.e000439.23","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2025083110540000000_6.1.e000439.24","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2407"},{"key":"2025083110540000000_6.1.e000439.25","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/ni.2407","article-title":"Technical considerations for functional sequencing assays","volume":"13","author":"Zeng","year":"2012","journal-title":"Nat Immunol"},{"key":"2025083110540000000_6.1.e000439.26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176185","article-title":"A comparison of per sample global scaling and per gene normalization methods for differential expression analysis of RNA-Seq data","volume":"12","author":"Li","year":"2017","journal-title":"PLoS One"},{"key":"2025083110540000000_6.1.e000439.27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1513\/AnnalsATS.201808-564PS","article-title":"Control of confounding and reporting of results in causal inference studies. guidance for authors from editors of respiratory, sleep, and critical care journals","volume":"16","author":"Lederer","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"2025083110540000000_6.1.e000439.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113354"},{"key":"2025083110540000000_6.1.e000439.29","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","volume":"366","author":"Raghu","year":"2012","journal-title":"N Engl J Med"},{"key":"2025083110540000000_6.1.e000439.30","unstructured":"Action for pulmonary fibrosis, 2018. Available: https:\/\/www.actionpulmonaryfibrosis.org\/"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2019-000439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T17:54:11Z","timestamp":1756662851000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2019-000439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,6,4]]},"published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1136\/bmjresp-2019-000439"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2019-000439","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}